ZVSA (ZyVersa Therapeutics) Other Financing: $0.00 Mil (TTM As of Mar. 2026)


ZVSA ZyVersa Therapeutics Inc ZVSA
30 GF Score
Price $0.14
! 1 Warning Sign
View Full Analysis

What is ZyVersa Therapeutics Other Financing?

ZyVersa Therapeutics ZVSA -23.70% 30 Other Financing is $0.00 Mil as of Mar. 2026. GuruFocus rates ZVSA with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

ZyVersa Therapeutics's Other Financing for the three months ended in Mar. 2026 was $0.00 Mil.

ZyVersa Therapeutics's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

ZyVersa Therapeutics Other Financing Historical Data

* Premium members only.

The historical data trend for ZyVersa Therapeutics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZyVersa Therapeutics Other Financing Chart

ZyVersa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 0.00 -0.10 -1.46 4.56 0.00

ZyVersa Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ZVSA
30GF Score
ZyVersa Therapeutics Inc ZVSA
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ZyVersa Therapeutics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $0.00 Mil mean?
ZyVersa Therapeutics (ZVSA) has a Other Financing of $0.00 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for ZyVersa Therapeutics and its competitors.
Is ZyVersa Therapeutics' Other Financing too high?
ZyVersa Therapeutics' current Other Financing is $0.00 Mil. Overall, ZyVersa Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does ZyVersa Therapeutics' Other Financing compare to AXIM and ISCO?
ZyVersa Therapeutics' Other Financing of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for ZyVersa Therapeutics and its competitors. ZyVersa Therapeutics's current Other Financing is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZyVersa Therapeutics stock overvalued right now?
ZyVersa Therapeutics (ZVSA) has a current Other Financing of $0.00 Mil. The current Other Financing is $0.00 Mil. ZyVersa Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For ZyVersa Therapeutics (ZVSA), the current Other Financing is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ZyVersa Therapeutics Business Description

Address 2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
30GF Score

Get the complete analysis for ZVSA

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.14
Price